Targeting microglial NLRP3 in the SNc region as a promising disease‐modifying therapy for Parkinson's disease

Targeting microglial NLRP3 in the SNc region as a promising disease‐modifying therapy for Parkinson's disease

Abstract Introduction Parkinson's disease (PD) is a neurodegenerative disorder characterized by progressive loss of dopaminergic (DA) neurons. Accumulating evidence has shown that activation of the NLR family pyrin domain‐containing 3 (NLRP3) inflammasome is an early and cardinal feature in PD...

Full description

Bibliographic Details
Main Authors:	Chen Qiao, Tao Dang, Yan Zhou, Yuan‐Zhang Zhou, Rong Zhao, Min Wang
Format:	Article
Language:	English
Published:	Wiley 2022-11-01
Series:	Brain and Behavior
Subjects:	disease‐modifying therapy dopaminergic neuron microglia NLRP3 Parkinson's disease
Online Access:	https://doi.org/10.1002/brb3.2784

Similar Items

Curcumin protects against rotenone-induced Parkinson's disease in mice by inhibiting microglial NLRP3 inflammasome activation and alleviating mitochondrial dysfunction
by: Long Xu, et al.
Published: (2023-05-01)

Genetic Imaging of Neuroinflammation in Parkinson’s Disease: Recent Advancements
by: Longping Yao, et al.
Published: (2021-07-01)

Targeting Microglial α-Synuclein/TLRs/NF-kappaB/NLRP3 Inflammasome Axis in Parkinson’s Disease
by: Yunna Li, et al.
Published: (2021-10-01)

The Role of Non-Coding RNAs in the Pathogenesis of Parkinson’s Disease: Recent Advancement
by: Hanwen Zhang, et al.
Published: (2022-06-01)

Inhibition of Calpain Attenuates Degeneration of Substantia Nigra Neurons in the Rotenone Rat Model of Parkinson’s Disease
by: Vandana Zaman, et al.
Published: (2022-11-01)

Dopamine signaling modulates microglial NLRP3 inflammasome activation: implications for Parkinson’s disease
by: Adrianne F. Pike, et al.
Published: (2022-02-01)

Studying the Pathophysiology of Parkinson’s Disease Using Zebrafish
by: Lisa M. Barnhill, et al.
Published: (2020-07-01)

Roles of stem cells in the treatment of Parkinson's disease
by: Yasaman Ebrahimikia, et al.
Published: (2018-10-01)

The Promise of the Zebrafish Model for Parkinson’s Disease: Today’s Science and Tomorrow’s Treatment
by: Khairiah Razali, et al.
Published: (2021-04-01)

Allelic difference in Mhc2ta confers altered microglial activation and susceptibility to α-synuclein-induced dopaminergic neurodegeneration
by: Itzia Jimenez-Ferrer, et al.
Published: (2017-10-01)

Cytokine Profiling in Human iPSC-Derived Dopaminergic Neuronal and Microglial Cultures
by: Evelyn Knappe, et al.
Published: (2023-10-01)

Substantia Nigra Hyperechogenicity Reflects the Progression of Dopaminergic Neurodegeneration in 6-OHDA Rat Model of Parkinson’s Disease
by: Siyan Zhang, et al.
Published: (2020-08-01)

A Focus on Astrocyte Contribution to Parkinson’s Disease Etiology
by: Giselle Prunell, et al.
Published: (2022-11-01)

Excessive Daytime Sleepiness in Parkinson’s Disease
by: Liu H, et al.
Published: (2022-09-01)

Current status of stem cell-derived therapies for Parkinson’s disease : from cell assessment and imaging modalities to clinical trials
by: Jang, Se Eun, et al.
Published: (2021)

Celastrol Inhibits Dopaminergic Neuronal Death of Parkinson’s Disease through Activating Mitophagy
by: Ming-Wei Lin, et al.
Published: (2019-12-01)

Glial cells in intracerebral transplantation for Parkinson’s disease
by: Nikola Tomov
Published: (2020-01-01)

Parkinson’s disease: general features, effects of levodopa treatment and future directions
by: Marco Aurelio M Freire, et al.
Published: (2010-11-01)

Mitochondrial Phenotypes in Parkinson’s Diseases—A Focus on Human iPSC-Derived Dopaminergic Neurons
by: Leonie M. Heger, et al.
Published: (2021-12-01)

The Relationship between Iron and LRRK2 in a 6-OHDA-Induced Parkinson’s Disease Model
by: Ruru Jia, et al.
Published: (2023-02-01)

Brain‐derived neurotrophic factor attenuates cognitive impairment and motor deficits in a mouse model of Parkinson's disease
by: E Chang, et al.
Published: (2021-08-01)

Modeling of the Progressive Degradation of the Nigrostriatal Dopaminergic System in Mice to Study the Mechanisms of Neurodegeneration and Neuroplasticity in Parkinson’s Disease
by: Anna Kolacheva, et al.
Published: (2022-12-01)

Degeneration of dopaminergic neurons due to metabolic alterations and Parkinson’s disease
by: Juhyun eSong, et al.
Published: (2016-03-01)

The Molecular Mechanisms of the Relationship between Insulin Resistance and Parkinson’s Disease Pathogenesis
by: Viviana A. Ruiz-Pozo, et al.
Published: (2023-08-01)

TFE3-Mediated Autophagy is Involved in Dopaminergic Neurodegeneration in Parkinson’s Disease
by: Xin He, et al.
Published: (2021-11-01)

Neuron-Astrocyte Interactions in Parkinson’s Disease
by: Ikuko Miyazaki, et al.
Published: (2020-12-01)

Understanding miRNA Based Gene Regulation in Parkinson’s Disease: An in silico Approach
by: Surya Narayan Rath, et al.
Published: (2020-03-01)

Role of G Protein-Coupled Receptors in Microglial Activation: Implication in Parkinson’s Disease
by: Chao Gu, et al.
Published: (2021-11-01)

Microglial AGE-albumin is critical for neuronal death in Parkinson's disease: a possible implication for theranostics
by: Bayarsaikhan E, et al.
Published: (2016-08-01)

Altered expression patterns of inflammation-associated and trophic molecules in substantia nigra and striatum brain samples from Parkinson’s disease, incidental Lewy body disease and normal control cases
by: Douglas Gordon Walker, et al.
Published: (2016-01-01)

Zonisamide Ameliorates Microglial Mitochondriopathy in Parkinson’s Disease Models
by: Satoshi Tada, et al.
Published: (2022-02-01)

Neuroprotective potential of Afzelin: A novel approach for alleviating catalepsy and modulating Bcl-2 expression in Parkinson's disease therapy
by: Khalid M. Alharthy, et al.
Published: (2024-02-01)

Triggering Receptor Expressed on Myeloid Cells 2 Protects Dopaminergic Neurons by Promoting Autophagy in the Inflammatory Pathogenesis of Parkinson’s Disease
by: Wei Huang, et al.
Published: (2021-11-01)

Animal Models of Autosomal Recessive Parkinsonism
by: Guendalina Bastioli, et al.
Published: (2021-07-01)

Searching for Biomarkers in the Blood of Patients at Risk of Developing Parkinson’s Disease at the Prodromal Stage
by: Elena A. Katunina, et al.
Published: (2023-01-01)

Combining Gene Transfer and Nonhuman Primates to Better Understand and Treat Parkinson’s Disease
by: Christelle Lasbleiz, et al.
Published: (2019-02-01)

Growth/differentiation factor-15 deficiency compromises dopaminergic neuron survival and microglial response in the 6-hydroxydopamine mouse model of Parkinson's disease
by: Venissa Machado, et al.
Published: (2016-04-01)

Neuroprotective effects of osmotin in Parkinson’s disease-associated pathology via the AdipoR1/MAPK/AMPK/mTOR signaling pathways
by: Jun Sung Park, et al.
Published: (2023-08-01)

Modeling Cell-Cell Interactions in Parkinson’s Disease Using Human Stem Cell-Based Models
by: Katrin Simmnacher, et al.
Published: (2020-01-01)

The role of microglial autophagy in Parkinson’s disease
by: Rui Zhu, et al.
Published: (2022-11-01)